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Abstract: Impaired exercise capacity is the core symptom of heart failure with preserved 
ejection fraction (HFpEF). We assessed effects of exercise training and Crataegus extract 
WS 1442 in HFpEF and aimed to identify mechanisms of action in an exploratory trial 
(German Clinical Trials Register DRKS00000259). 140 sedentary HFpEF NYHA II 
patients on standard treatment received eight weeks of aerobic endurance training and half 
were randomized to WS 1442 900 mg/day. Symptoms, 2 km walking time (T2km), 
parameters of exercise tolerance, cardiac and vascular function, muscular efficiency and 
skeletal muscular haemoglobin oxygen saturation (SO2) measured during a treadmill 
protocol were captured at baseline and after eight weeks. Adverse events were recorded 
during the trial. Mechanisms of action were explored by correlation and path analyses of 
changes. Symptoms and exercise capacity improved with training, but correlations between 
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improvements were low and path models were rejected. SO2 increased, decreased or 
undulated with increasing exercise intensity in individual patients and was not altered by 
training. WS 1442 improved T2km (-12.7% vs. -8.4%, p = 0.019), tended to improve 
symptoms and to pronounce SO2-decrease with increasing exercise, an indicator of oxygen 
utilisation. Endurance training and WS 1442 were safe and well tolerated in combination 
with standard drug treatment.  
Keywords: heart failure; HFpEF; training; Crataegus; WS 1442; NIRS  
 
1. Introduction 
At least half of patients with chronic heart failure suffer from diastolic dysfunction with preserved 
left ventricular ejection fraction (HFpEF) [1]. Typically, these patients are elderly women with a long-
standing history of arterial hypertension [1]. Impaired endothelial NO-availability has been implicated 
in the pathophysiology of HFpEF [2-6]. Current treatment guidelines for this patient population 
recommend optimal treatment of underlying diseases / risk factors and lifestyle modifications such as 
moderate exercise training [7, 8]. More specific recommendations to improve symptoms, quality of 
life, and prognosis have not yet been established. 
Crataegus extract WS 1442 has been demonstrated to improve symptoms and exercise tolerance in 
patients with heart failure, New York Heart Association (NYHA) stage II to III [9, 10], but no specific 
trials in patients with HFpEF have been conducted. WS 1442 has been demonstrated to increase 
thickness and reduce stiffness of the endothelial inner surface layer (the glycocalix), a sensor of blood-
flow induced shear stress and modulator of endothelial NO-synthesis [11]. The extract activates 
endothelial and red blood cell NO-synthase [12-14], increases endothelial NO-release and improves 
endothelium-dependent arterial function in animal models of aging and hypertension [15, 16]. The 
vascular effects are strongly related to the high content of oligomeric procyanidins in the extract [13]. 
In addition, WS 1442 increases cardiac muscle force of contraction via an ATP-independent 
mechanism [17], has shown positive effects on remodelling in animal models of increased afterload 
[18-20] and increases skeletal muscle mitochondrial density and fibre diameter [21]. It has not been 
determined to what extent the reported vascular, cardiac and skeletal muscular effects contribute to the 
clinical benefit in heart failure patients.  
Therefore, the present exploratory study aimed to assess the effects of WS 1442 when added to 
standard cardiological treatment and exercise training, on symptoms and quality of life, exercise 
capacity, cardiac, vascular, and muscular function in patients with HFpEF, stage NYHA II. Based on 
the comprehensive assessment, we aimed to identify mechanisms underlying the clinical benefit. 
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2. Method, Results, Discussion 
 
2.1. Method 
 
2.1.1. Design 
 
The monocentric prospective randomized controlled open-label phase IV trial (German Clinical 
Trials Register DRKS00000259; EudraCT 2009-015005-39) was conducted according to ICH-GCP 
standards and local regulations after favourable opinion from the independent ethics committee of the 
Landesärztekammer Baden-Württemberg (Baden-Wuerttemberg State Chamber of Physicians), 
Stuttgart, Germany, and approval by the Federal Institute for Drugs and Medical Devices (BfArM). 
 
2.1.2. Patients 
 
Men and women (1:1, having given written informed consent) with a diagnosis of heart failure 
NYHA II, echocardiographically assessed resting LVEF > 40%, NT-pro BNP < 450 ng/ml and less 
than 2 hours of physical activity per week were recruited from a large ambulatory cardiological office 
in Karlsruhe, Germany. Exclusion criteria included severe or acute cardiac or general diseases, atrial 
flutter, pacemaker or ICD, significant deterioration of cardiac complaints during the preceding week, 
treatment with cardiac glycosides, hawthorn or other herbal drugs. 
 
2.1.3. Treatments 
 
All patients were continued on standard cardiological treatment for heart failure with LVEF > 40 % 
according to the German and European guidelines [7, 8] and received eight weeks of exercise training. 
The training comprised 90 minutes training sessions twice a week according to a detailed written 
manual conducted by educated trainers from the Institute of Sports and Sport Science, Karlsruhe 
Institute of Technology. The training sessions included education, warm up, 50 minutes of aerobic 
exercise (walking), and relaxation. Exercise intensity was individually tailored to a target heart rate 
corridor using Polar RS800
TM
 heart rate monitors. The target corridor boundaries corresponded to the 
individual aerobic and anaerobic lactic acid thresholds, determined during the baseline treadmill 
exercise test and calculated by the software Ergonizer, Version 3.1.0 (Prof. Dr. K. Röcker, Freiburg). 
After inclusion patients were randomized 1:1 to training or training and eight weeks open label 450 
mg b.i.d. WS
®
 1442 as film coated tablets (Crataegutt
®
 novo 450 mg). WS 1442 is a dry extract from 
hawthorn leaves with flowers, drug-extract ratio 4 – 6.6 : 1, extraction solvent ethanol 45% (w/w). The 
extract is adjusted to 17.3 to 20.1% oligomeric procyanidins (manufacturer: Dr. Willmar Schwabe 
GmbH & Co. KG, Karlsruhe). Treatment was assigned to included patients by the investigator, 
opening a sealed randomization envelope with the lowest available randomization number for the 
patient’s gender. Envelopes were generated by a biometrician, not involved in study conduct, based on 
two randomization lists (for men and women) generated with software Randomizer 
(www.randomizer.at) using a block-size of 10. 
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2.1.4. Outcomes 
 
Symptoms and Quality of Life were captured by the Kansas City Cardiomyopathy Questionnaire 
(KCCQ [22, 23]). Exercise tolerance was assessed (1) for everyday moderate physical activities by the 
Freiburg Questionnaire of Physical Activity [24] and the 2-km Walking Test [25] and (2) for peak 
exercise capacity by a treadmill cardiopulmonary exercise protocol. The exercise protocol was 
performed in two-minute bouts with ascending intensity and a rest of 30 seconds between bouts, and 
terminated at (1) subjective exhaustion or (2) at a maximal safe heart rate individually determined by 
the treating cardiologist based on bicycle exercise testing at screening. Time to 2 mmol/l, 4 mmol/l, 
and individual lactate threshold [26], subjective exertion [27], VO2, VCO2 and end-expiratory CO2 
(Cortex MetaMax
®
 3B spirometer) were assessed during treadmill (Woodway PPS 55med-I) exercise. 
In addition, a finger pulse plethysmography signal (BMEYE Nexfin HD Monitor) was recorded during 
treadmill exercise and indices of cardiac and vascular function (heart rate, blood pressure, cardiac 
output, stroke volume, dP/dt (maximum first derivative of pressure), and peripheral vascular 
resistance) were automatically calculated from the plethysmography signal. At the end of the exercise 
testing, a blood sample was drawn from the hyperaemic earlobe to calculate cardiac output from 
capillary blood and expiratory CO2 concentrations [28]. Muscular efficiency was determined by the 
ratio of VO2 and workload [29] at maximal exercise. Skeletal muscular haemoglobin oxygen saturation 
(SO2) was measured during treadmill exercise by a near infrared spectroscopy calf sensor (Hamamatsu 
Monitor NIRO 100). All outcomes as well as resting NT-pro-BNP were measured at baseline and after 
eight weeks. Adverse events were recorded to document tolerability and safety of applied treatments. 
Clinically relevant changes or new abnormal findings in safety laboratory parameters or physical 
examination were classified as adverse events.  
 
2.1.5. Analysis 
 
In line with the trial’s exploratory nature, no primary endpoint was defined and no formal sample 
size calculation was performed. A sample size of n = 140 was considered adequate based on previous 
experience [30] and for a planned path analysis with eight variables and 15 relations [31]. 
Efficacy analysis was conducted according to the intention-to-treat principle in all patients 
randomized with any efficacy data after randomization. Efficacy outcomes were analysed descriptively 
and treatment effects in the training only group were analysed by Wilcoxon rank sum test for change 
from baseline. Parameters measured at every exercise level (e.g. SO2, Borg’s scale) are reported 
descriptively until levels with n ≥ 5 in the respective group. Spearman’s rank sum correlation 
coefficients were calculated between changes in symptoms, parameters derived from treadmill exercise 
testing, and 2 km walking time as well as correlations between these parameters and training intensity. 
To identify mechanisms of exercise training, a confirmatory path analysis was conducted for the 
exercise training only group, based on the correlation matrix and on changes between baseline and 
eight weeks in efficacy endpoints. Because data did not support the a priori planned path model, 
exploratory modifications were modelled. 
Next, group differences in treatment effects were explored by repeated measurements ANOVA, 
with significant interactions between treatment and visit indicating treatment differences. To identify 
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mechanisms of WS 1442, necessary modifications of the path model in the group treated with 
WS 1442 were explored. Analyses were done with SAS version 9.2 (SAS Institute Inc., Cary, NC). 
Finger plethysmography data were dominated by movement artefacts, especially at higher exercise 
levels. Therefore it was decided at blind data review to average data for exercise levels 1 to 3 and to 
calculate the difference to the average at level 0. Variance was still high and no training effects were 
detected. Therefore, parameters derived from the plethysmography signal were excluded from path 
analysis. 
The 4 mmol/l lactic acid threshold was only reached by a minority of patients at baseline and after 
training and was therefore excluded from further analyses. 
Descriptive safety analysis was done in all patients receiving treatment at least once. 
 
2.2. Results 
 
2.2.1. Patients and baseline data 
 
In total, 70 men and 70 women were randomized to study treatment between December 2009 and 
June 2011. For 7 patients (5 training and WS 1442, 2 training only) no efficacy data were available 
after randomization, therefore 133 patients were analysed for efficacy (figure 1). Mean age was 62 
years, 90% of patients suffered from arterial hypertension, 40% from ischemic heart disease, 27% had 
hypercholesterolemia, and 82% were overweight (table 1). Nearly all patients received cardiovascular 
baseline medication. Two-thirds were on drugs inhibiting the renin-angiotensin-aldosterone system, 
about 61% received beta-adrenoceptor antagonists. Baseline symptoms were mild to moderate 
reflected by a KCCQ sum score of 76 out of 100. NT-proBNP (median 85 ng/l, interquartile range 46 - 
170 ng/l) indicated well compensated cardiac status. Treatment groups did not differ significantly in 
demographics or disease characteristics.  
Exercise capacity was moderately limited: Treadmill testing was terminated after 10.3 minutes, with 
a relative oxygen uptake of 22.0 mlO2/min*kg, a cardiac output of 14.5 l/min, and a muscular 
efficiency of 17.8 mlO2/min*W at severe subjective exertion (Borg scale 15.7). Individual lactate 
threshold was reached after 9.5 minutes and patients needed 22.2 minutes for the 2 km walking test 
(table 2). 
Calf muscle oxygenation showed an unexpected pattern: In some patients, oxygen saturation 
increased with increasing exercise intensity until termination due to exhaustion, in some it undulated, 
and in others it decreased (figure 2).  
2.2.2. Study treatment 
 
Patient adherence to exercise training was high but somewhat lower in the group taking WS 1442: 
89% of patients in the training only group participated in more than 10 sessions, 79% in the group 
combined with WS 1442. Mean times in the target heart rate corridor were 391 and 379 minutes. 
Medication compliance based on pill counting was > 97%. 
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2.2.3. Treatment effects in training only group  
 
Symptoms and exercise capacity improved after eight weeks of exercise training. KCCQ scores 
improved significantly as well as exercise time, lactate threshold, muscular efficiency, subjective 
exertion at exercise level 3, physical activity and 2 km walking time (table 2). Exercise time during 
treadmill testing, cardiac output and muscular efficiency at maximal exercise increased, while relative 
oxygen uptake at maximal exercise remained unchanged at 22.2 ml/min*kg. Subjective exertion at 
exercise level 5 (from 14.8 to 14.6, p=0.70) and at maximal exercise did not improve significantly.  
 
Figure 1. Patient disposition. 
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Decrease of skeletal muscle oxygen saturation from exercise level 1 to higher levels was hardly 
affected by training (figure 3a). NT-proBNP increased minimally by 18 ng/l (p=0.07). 
Correlations between changes in symptoms, parameters derived from treadmill exercise testing, and 
2 km walking time were low as were correlations between these parameters and training intensity 
(Spearman’s rank correlation, nearly all rho < 0.4 and p > 0.05). In line with the low correlations, 
effects in both, planned and modified path models were generally very small and non-significant.   
Table 1. Study sample characteristics.  
Percent of patients or mean value (± SD) 
Treatment Group 
Training + WS 1442 
(n=70) 
Training 
(n=70) 
Age (years) 62 ± 9.0 62 ± 7.8 
Cardiovascular disease/ risk factor   
Hypertension 91 % 87 % 
Ischemic heart disease 43 % 36 % 
Mitral insufficiency 11 % 10 % 
Hyperlipidaemia 33 % 33 % 
Diabetes mellitus 16 % 9 % 
Thyroid disorder 17 % 13 % 
Smoking 9 % 9 % 
Body mass index (kg/m
2
) 30.2 ± 5.5 29.7 ± 4.7 
Concomitant medication 99 % 96 % 
 ACE-inhibitors, AT2-antagonists 69 % 64 % 
 Beta blockers 64 % 57 % 
 Platelet aggregation inhibitors, coumarines 64 % 49 % 
 Lipid lowering drugs 61 % 56 % 
 Calcium-antagonists 27 % 21 % 
 Anti-diabetics 20 % 11 % 
 Nitrates, vasodilating drugs, other cardiacs 19 % 11 % 
 Diuretics 17 % 10 % 
 Thyroid therapeutics 23 % 14 % 
 
 
2.2.4. Effects of WS 1442 
 
Absolute improvements of symptoms and quality of life tended to be larger with training and 
WS 1442 compared to training alone (table 2). The most pronounced difference was in the KCCQ-
subscore “Symptoms”, mainly based on improvements in dyspnoea and fatigue (figure 4).  
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Table 2. Effects of 8 weeks treatment on symptoms and exercise capacity 
 Treatment 
 
(mean ± SD) 
Training only  Training + WS 1442 
Baseline Change  Baseline Change 
KCCQ      
Physical limitation 85 ± 17 4 ± 15*  82 ± 17 6 ± 15 
Symptom stability 57 ± 29 9 ± 35  60 ± 29 3 ± 29 
Symptoms  76 ± 18 5 ± 14*  70 ± 22 10 ± 17 
Self-efficacy 70 ± 21 2 ± 17  70 ± 20 3 ± 15 
Social limitation 79 ± 23 5 ± 16*  76 ± 25 9 ± 20 
Quality of life 71 ± 24 9 ± 17*  69 ± 23 11 ± 18 
Exercise capacity      
Freiburg Questionnaire of Physical 
Activity 
27 ± 23 14 ± 27*  27 ± 26 14 ± 29 
Time for 2 km walking test (min) 21.4 ± 2.4 -1.9 ± 2.0*  23.0 ± 3.1 -2.9 ± 2.4
†
 
Treadmill test, time to termination (min) 11.1 ± 3.0 1.3 ± 2.0*  9.6 ± 3.7 1.3 ± 2.7 
Treadmill test, maximum exercise       
relative O2 uptake (ml/min/kg) 22.2 ± 4.2 0.0 ± 2.5  21.9 ± 4.6 -0.2 ± 2.8 
cardiac output (l/min) 14.5 ± 3.6 0.8 ± 2.4*  14.4 ± 3.8 0.5 ± 2.7 
muscular efficiency (mlO2/W) 16.9 ± 4.3 -1.4 ± 4.1*  18.6 ± 5.4 -0.8 ± 4.7 
Borg subjective exertion scale 15.7 ± 2.0 -0.1 ± 1.7  15.5 ± 2.1 -0.6 ± 2.0 
Time to lactate threshold (min) 6.8 ± 2.4 0.9 ± 2.2*  5.4 ± 2.8 1.1 ± 2.2 
*
 p<0.05, Wilcoxon rank sum test for change from baseline in training only group 
†
 p=0.019, repeated measurements ANOVA, interaction visit*treatment in total sample 
 
Figure 2. Haemoglobin oxygen saturation in calf muscle was measured by NIRS during 
treadmill exercise. The exercise protocol comprised two-minute bouts of increasing 
intensity (large symbols) and 30 seconds rests between bouts (small symbols). Baseline 
data from three exemplary patients are displayed. 
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Figure 3. (a) Effects of interventions on calf muscle oxygenation with increasing exercise. 
Haemoglobin oxygen saturation (%) in calf muscle was measured by NIRS during 
treadmill exercise with increasing intensity levels at baseline and after eight weeks of 
treatment. Absolute decrease of oxygen saturation versus exercise level 1 was calculated 
for every patient and averaged for the training only group (mean ± SEM). (b) The same 
data are shown for the group receiving training plus WS 1442. (c) For every patient, the 
change from baseline in the decrease of oxygen saturation vs. exercise level 1 was 
calculated for every exercise level. Data were averaged for both groups (mean ± SEM). 
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Mean time required to walk 2 km was significantly reduced by additional intake of WS 1442: It 
decreased from to 21 to 20 minutes in the training group (-8.4%), and from 23 to 20 minutes in patients 
taking WS 1442 (-12.7%, p = 0.019 for group difference). 
Parameters measured during treadmill exercise improved by a comparable extent in both treatment 
groups. Subjective exertion ratings tended to improve more with WS 1442 at higher exercise levels 
(figure 5).  
Decrease of skeletal muscle oxygen saturation from exercise level 1 to higher levels tended to be 
more pronounced after WS 1442 and training compared to training alone (figure 3b and c). 
Correlations of changes during treatment and effects in path models were generally small and non-
significant in the total sample. 
 
Figure 4. Absolute change of KCCQ-rated items from the subscore “Symptoms” during 
eight weeks of treatment. 
 
 
 
2.2.5. Tolerability and Safety 
 
Professionally supervised exercise training for eight weeks was generally safe. The most frequently 
reported adverse events were related to the musculo-skeletal system and injuries, but none was serious. 
Frequency of adverse events was not higher under WS 1442 treatment (13% of patients) than 
without (17%, table 3). One serious adverse event (bacterial urogenital infection) occurred; it was 
considered unrelated to WS 1442 by the investigator. Events probably or possibly related to WS 1442 
or drug interactions were not reported throughout the trial.  
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Figure 5. Decrease of patient rated subjective exertion on Borg’s scale during treadmill 
exercise with increasing intensity levels from baseline to after eight weeks of treatment 
(mean ± SEM). 
 
 
 
Table 3. Safety and tolerability. 
 
Percent of patients 
Treatment Group 
Training + WS 1442 
(n=70) 
Training 
(n=70) 
Adverse events   
total 13 % 17 % 
musculoskeletal and injuries 7 % 7 % 
infections 6 % 7 % 
cardiac 0 % 1 % 
gastrointestinal 0 % 1 % 
psychiatric 0 % 1 % 
serious 1 % 0 % 
fatal 0 % 0 % 
 causal relationship to drug likely or possible 0 %  
 
 
 
-1.5
-1
-0.5
0
0.5
1 2 3 4 5 6 7
Exercise level 
Training only Training + WS 1442
Sports 2014, 2 70 
 
 
 
2.3. Discussion 
 
2.3.1. Training effects 
 
Our sample of sedentary patients with HFpEF, already treated according to current guidelines, 
significantly benefitted in symptoms and quality of life from endurance exercise training. Patients 
reached a score of 80 to 90 out of 100 in important KCCQ subscales indicating only minimal 
remaining symptoms. This observation is in line with previous reports and supports the 
recommendation of endurance exercise training in diastolic heart failure [32, 33, 34]. Professionally 
supervised training was generally safe. However, seven per cent of patients experienced non-serious 
musculo-skeletal events or injuries, highlighting the need of professional supervision to prevent more 
frequent or serious complications. 
Surprisingly, improvements in symptoms, 2 km walking time, and parameters derived from the 
treadmill protocol were not correlated. Our interpretation is that parameters of exercise capacity 
developed in healthy trained populations, such as lactate thresholds, are not adequate to describe 
limitations in everyday physical activities and symptoms in sedentary heart failure patients. 
Limitations of everyday physical activity probably result from a heterogeneous array of factors beyond 
cardiovascular markers [35, 36]. Therefore we were not able to better describe the modes of action of 
exercise training by the technologies and analyses employed. Anecdotal reports from the training 
groups in our study indicated that social interaction, psychological factors and getting used to physical 
activity are important moderators of symptomatic improvement. 
 
2.3.2. Effects of WS 1442 
 
Efficacy of WS 1442 for symptomatic treatment of heart failure NYHA II has been demonstrated in 
a number of placebo-controlled trials [9, 10].  As our patients already reached a score of 80 to 90 out 
of 100 in important KCCQ subscales with training only, there was little room for further improvement 
with WS 1442 and our trial was underpowered to statistically prove the additional symptomatic benefit 
we observed. In a measure of everyday physical activity that did not have such a ceiling effect, the 2 
km walking test, a significant benefit could be demonstrated. The Freiburg questionnaire only reflected 
the increase in physical activity by participation in the training, and therefore demonstrated no group 
difference. The exercise protocol was terminated at the pre-specified maximal heart rate in the majority 
of cases, not for exhaustion. This stopping criterion was not changed during the trial. Therefore 
improvements in treadmill exercise parameters were moderate without group differences. A trend of 
less subjective exertion with WS 1442 might indicate that exercise until subjective exhaustion shows a 
group difference. Finger plethysmography was dominated by movement artefacts preventing 
meaningful analysis of cardiac and vascular function. More stable and validated techniques should be 
used in future clinical trials on WS 1442 modes of action. 
Adding WS 1442 to standard cardiological drug treatment was safe, no interactions were reported. 
This is in line with experience during the SPICE trial [37]. In this largest trial ever conducted with 
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crataegus extract, adding WS 1442 to optimal drug treatment in patients with heart failure NYHA II or 
III and LVEF ≤35% was safe [38].   
2.3.3. Skeletal muscle oxygenation 
 
The pattern of skeletal muscle oxygen saturation with increasing exercise in our sample of 
sedentary treated patients with heart failure was significantly different from the steady decrease that 
has been reported in healthy trained untreated subjects [39, 40]. The observation that a considerable 
proportion of patients can increase skeletal muscle oxygen saturation with increasing exercise and 
terminates exercise at high muscle oxygen saturation indicates that oxygen supply to the muscle is not 
limiting exercise capacity in these patients. Oxygen utilization might be a limiting factor [41]. In line 
with this observation, a loss of oxidative type-1 muscle fibres and a reduction of capillary to fibre ratio 
have been reported in HFpEF patients [42, 43]. Moreover, in our sample heterogeneity of oxygen 
saturation patterns with increasing exercise was considerable. Deficits in oxygen supply and oxygen 
utilization might contribute differentially in individual patients to the limitation in exercise capacity. 
Therefore, individual patients might respond differentially to treatment strategies. NIRS provides a 
non-invasive tool to guide treatment strategies in treated patients with HFpEF still suffering from 
limitations in exercise capacity. We observed that training plus WS 1442 pronounced the average 
decrease of oxygen saturation with increasing exercise while training alone had no effect on this 
parameter. Assuming that blood flow to the muscle has not been reduced by training and WS 1442, 
decrease of oxygen saturation with increasing exercise is an indicator of oxygen utilization. Chronic 
intake of WS 1442 has been reported to increase skeletal muscle mitochondrial density and to induce a 
shift towards oxidative type-1 fibres [21]. Therefore we postulate that WS 1442 might improve oxygen 
utilization in the skeletal muscle.  
 
2.3.4. Limitations  
 
All patients in our trial received exercise training. Therefore we cannot quantify to what extent the 
observed improvements are due to training or are unspecific (e.g. Hawthorne effect). However, 
efficacy of exercise training in diastolic heart failure has been reported in controlled trials [32, 33, 34], 
and changes in untrained individuals are small. Therefore it is unlikely that the considerable effects we 
observed are unspecific in nature. 
Our control group did not receive placebo because our main interest was the correlation between 
changes to explore underlying mechanisms, not absolute group differences. While treatments applied 
in our trial correspond to the setting in routine clinical practice, we cannot exclude that non-specific 
effects have contributed to the observed group differences. However, the efficacy of WS 1442 has 
been demonstrated in previous placebo-controlled trials [9, 10].  
Our trial was not powered to prove treatment effects of WS 1442 and hence is prone to type-II error, 
i.e. the sample was too small for the observed treatment differences to reach statistical significance. 
For example, improvements in all but one KCCQ-subscores were larger with WS 1442 than with 
training alone, for the subscore “symptoms” mean effect was twice as big. Therefore we were not able 
to finally prove or disprove treatment differences. 
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We were not able to clarify the mechanisms underlying the clinical benefit of training and WS 1442 
with the applied technologies and analyses. Future clinical trials on the mode of action should apply 
better established and more stable measures of vascular and cardiac function. 
 
4. Conclusion 
Treated sedentary patients with heart failure with preserved ejection fraction benefit in symptoms 
and quality of life from endurance exercise training. Professionally supervised training is safe in this 
population. WS 1442 tended to further improve symptoms and everyday exercise capacity. This extract 
can be safely combined with standard drug treatment of heart failure. 
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